SacredBod's longer take on Muira Puama — context the structured blocks above don't capture.
Muira puama is the textbook example of a supplement where traditional reputation vastly exceeds clinical validation. In the Amazon, it has been called “potency wood” for generations. In the medical literature, it has barely been tested as a standalone therapy.
The traditional story vs. the evidence
The most frequently cited “clinical” reference is a 1994 report by Dr. Jacques Waynberg involving 262 men with low libido or impotence who took 1-1.5 g of muira puama extract daily. According to secondary sources, 60% reported increased sexual desire and 50% reported improved erectile function. However, this was not a peer-reviewed RCT published in a PubMed-indexed journal — it was a clinical observation published in a natural medicine newsletter. The only peer-reviewed human trial (Waynberg & Brewer, 2000) tested a combination of muira puama and ginkgo biloba in 202 women, finding that 65% experienced improved sexual desire and orgasm frequency. This is promising for women, but does not establish efficacy in men.
The multi-ingredient problem
The 2018 Nguyen pilot study tested Revactin® — a combination of muira puama, ginger, guarana, and L-citrulline — in 54 men with erectile dysfunction. Approximately 50% showed improvement in IIEF scores over 3 months. However, because the product contains four active ingredients, it is impossible to attribute benefit to muira puama specifically. The same limitation applies to the animal work (Ferrini et al., 2018) showing iNOS upregulation in penile tissue, which also tested a four-ingredient combination.
Mechanism speculation
Preclinical work suggests muira puama may increase acetylcholine receptor sensitivity, reduce stress-induced cortisol elevation, and enhance nitric oxide signaling in erectile tissue. These mechanisms are biologically plausible but unconfirmed in humans. Without a standalone muira puama RCT in men, any claims remain speculative.
Honest comparison
For libido and erectile support, tongkat ali has stronger human evidence. Maca has multiple RCTs in men. Yohimbine has genuine pharmacological efficacy albeit with side effects. Muira puama is best viewed as a low-risk, low-evidence traditional tonic — reasonable to experiment with if expectations are modest, but not a reliable primary therapy.